Compare GSK plc (GSK) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs NIO Inc. — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while NIO Inc. trades at $3.58 (market cap $8.62B). The key difference: GSK plc is far larger — about 10.7× NIO Inc.'s market cap, and GSK plc pays a 3.9% dividend while NIO Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and NIO Inc. for 81 Days on average.
| GSK | NIO | |
|---|---|---|
Market Cap | $91.88B | $8.62B |
Volume | 7,730,529 | 39,648,517 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $7.46 |
52-Week Low | $43.24 | $3.37 |
Typical Hold Time | 93 Days | 81 Days |
Enterprise Value | $111.88B | $6.52B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
NIO trades at $3.58, up 1.13% in the last session but near a 52-week low amid a bearish technical trend. The company reported Q3 2026 deliveries up 25.4% and recently formed a strategic battery-swap partnership with Geely, yet it continues to post net losses with a -4.17% net margin. Analyst consensus is a 'Buy' with a $6.23 price target, but high debt and negative cash flows pose challenges.
The outlook remains cautious; revenue growth and partnership potential offer upside, but persistent losses, cash burn, and intense EV competition present significant risks. Investors should weigh the long-term battery-swap network expansion against near-term financial instability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
